Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SRNE |
---|---|---|
09:32 ET | 11489 | 0.0005 |
09:36 ET | 175 | 0.0095 |
09:38 ET | 200 | 0.0095 |
09:39 ET | 200 | 0.0085 |
09:57 ET | 200 | 0.0085 |
10:10 ET | 625 | 0.0085 |
10:12 ET | 800 | 0.0085 |
10:17 ET | 125 | 0.0095 |
10:50 ET | 100 | 0.0085 |
10:51 ET | 200 | 0.0085 |
11:22 ET | 100 | 0.0085 |
11:29 ET | 3000 | 0.0085 |
11:58 ET | 400 | 0.0085 |
12:00 ET | 73833 | 0.0095 |
12:50 ET | 118 | 0.0095 |
12:52 ET | 1600 | 0.0095 |
01:48 ET | 150 | 0.0095 |
01:53 ET | 600 | 0.0095 |
02:02 ET | 156 | 0.0095 |
02:06 ET | 230 | 0.0095 |
02:15 ET | 1000 | 0.0095 |
02:31 ET | 100 | 0.0095 |
02:38 ET | 400 | 0.0095 |
02:47 ET | 1000 | 0.0095 |
03:27 ET | 100 | 0.0095 |
03:52 ET | 136 | 0.0095 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sorrento Therapeutics Inc | 6.7M | 0.0x | --- |
Molecular Templates Inc | 7.8M | -0.3x | --- |
Centogene NV | 11.2M | -0.3x | --- |
Cidara Therapeutics Inc | 53.4M | -1.4x | --- |
Bioqual Inc | 64.8M | 67.8x | -25.28% |
Neptune Wellness Solutions Inc | 88.8K | 0.0x | --- |
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.7M |
---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.87 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.